◄ back to all posts
Financial data and stock pages provided by
Fintel.io
EBS: Emergent Biosolutions, Inc. Stock
Written by | Jul 6, 2018
Print FriendlySIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3,261.09 |
| Enterprise Value ($M) | 3,843.50 |
| Book Value ($M) | 987.50 |
| Book Value / Share | 19.21 |
| Price / Book | 3.28 |
| NCAV ($M) | -637.70 |
| NCAV / Share | -12.35 |
| Price / NCAV | -5.08 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.03 |
| Return on Assets (ROA) | 0.06 |
| Return on Equity (ROE) | 0.07 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.28 |
| Current Ratio | 2.13 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 528.50 |
| Assets | 2,153.70 |
| Liabilities | 1,166.20 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 89.80 |
| Net Income | 62.70 |
| Earnings Per Share Diluted | 1.22 |
| Earnings Per Share Basic | 1.25 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 41.80 |
| Cash from Investing | -897.20 |
| Cash from Financing | -897.20 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.04 | -3.42 | |
| 13G/A | BlackRock Inc. | 13.20 | 3.96 | |
| 13G/A | Dimensional Fund Advisors Lp | 3.32 | -24.79 | |
| 13G/A | Broadfin Capital, LLC | 1.70 | ||
| 13G/A | Bank of New York Mellon Corp | 4.81 | 274.63 | |
| 13G/A | Loomis Sayles & Co L P | 2.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| EBS / Emergent Biosolutions, Inc. 10-Q – Quarterly Report – 10-Q | ||
| EBS / Emergent Biosolutions, Inc. 10-Q – Quarterly Report – 10-Q | ||
| EBS / Emergent Biosolutions, Inc. 10-Q Quarterly Report 10-Q | ||
| EBS / Emergent Biosolutions, Inc. null (Annual Report) | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 15,414 | 231,300 | 6.66 | |
| 19,785 | 279,200 | 7.09 | |
| 20,693 | 299,700 | 6.90 | |
| 13,823 | 190,200 | 7.27 | |
| 33,017 | 268,900 | 12.28 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BXLT – Baxalta Incorporated | CBM – Cambrex Corp. |
| CTLT – Catalent Inc. | HSP – Hospira |
| JNJ – Johnson & Johnson |
Financial data and stock pages provided by
Fintel.io
